Siat1ΔP1 has improved recovery from cyclophosphamide-induced myelosuppression
Day . | WT, × 109/L . | Siat1ΔP1, ×109/L . | P . |
|---|---|---|---|
| 0 | 0.335 ± 0.150 | 0.370 ± 0.166 | .391 |
| 4 | 0.036 ± 0.007 | 0.055 ± 0.006 | .007 |
| 5 | 0.142 ± 0.078 | 0.287 ± 0.090 | .050 |
| 6 | 1.59 ± 0.42 | 2.55 ± 0.41 | .016 |
| 7 | 0.323 ± 0.245 | 0.241 ± 0.099 | .557 |
Day . | WT, × 109/L . | Siat1ΔP1, ×109/L . | P . |
|---|---|---|---|
| 0 | 0.335 ± 0.150 | 0.370 ± 0.166 | .391 |
| 4 | 0.036 ± 0.007 | 0.055 ± 0.006 | .007 |
| 5 | 0.142 ± 0.078 | 0.287 ± 0.090 | .050 |
| 6 | 1.59 ± 0.42 | 2.55 ± 0.41 | .016 |
| 7 | 0.323 ± 0.245 | 0.241 ± 0.099 | .557 |
Age- and sex-matched female Siat1ΔP1 (n = 29) and C57BL/6 (WT; n = 32) mice received 200 mg/kg cyclophosphamide on day 0. Peripheral blood was withdrawn and granulocyte counts were determined, as described under the first subheading within “Materials and methods.” Values are means ± SEM. For counts taken on days 4-7, n = 4 for each genotype. P values, calculated using the Student t test, compare WT and Siat1ΔP1 blood.